Will the launch of ‘Giotrif’ change the dynamics of the Korean cancer treatment market?

Intense attention has been focused on ‘Giotrif’ calling itself the irreversible ErbB Family Blocker.

Boehringer Ingelheim Korea held a press conference to celebrate the launch of insurance benefit for EGFR (Epidermal Growth Factor Receptor) mutation positive nonsmall-cell lung cancer treatment ‘Giotrif(generic name: Afatinib)’, and showed the up-to-date treatment information of nonsmall-cell l...